EX-99.2 3 a2020q4exhibit992.htm EX-99.2
Exhibit 99.2

Johnson & Johnson and Subsidiaries |  |  |  |  |  |  |  |  |
Supplementary Sales Data |  |  |  |  |  |  |  |  |
(Unaudited; Dollars in Millions) | FOURTH QUARTER
|  |  |  |  | Percent Change
| 2020 |  | 2019 |  | Total |  | Operations |  | Currency
Sales to customers by |  |  |  |  |  |  |  |  |
geographic area |  |  |  |  |  |  |  |  |
U.S. | $11,809 |  | 10,774 |  | 9.6 | % | 9.6 |  | -
Europe | 5,271 |  | 4,663 |  | 13.0 |  | 7.7 |  | 5.3
Western Hemisphere excluding U.S. | 1,404 |  | 1,495 |  | (6.1) |  | 2.9 |  | (9.0)
Asia-Pacific, Africa | 3,991 |  | 3,815 |  | 4.6 |  | 0.7 |  | 3.9
International | 10,666 |  | 9,973 |  | 7.0 |  | 4.3 |  | 2.7
Worldwide | $22,475 |  | 20,747 |  | 8.3 | % | 7.1 |  | 1.2
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries |  |  |  |  |  |  |  |  |
Supplementary Sales Data |  |  |  |  |  |  |  |  |
(Unaudited; Dollars in Millions) | TWELVE MONTHS
|  |  |  |  | Percent Change
| 2020 |  | 2019 |  | Total |  | Operations |  | Currency
Sales to customers by |  |  |  |  |  |  |  |  |
geographic area |  |  |  |  |  |  |  |  |
U.S. | $43,133 |  | 42,097 |  | 2.5 | % | 2.5 |  | -
Europe | 18,980 |  | 18,466 |  | 2.8 |  | 2.0 |  | 0.8
Western Hemisphere excluding U.S. | 5,335 |  | 5,941 |  | (10.2) |  | 0.4 |  | (10.6)
Asia-Pacific, Africa | 15,136 |  | 15,555 |  | (2.7) |  | (3.1) |  | 0.4
International | 39,451 |  | 39,962 |  | (1.3) |  | (0.2) |  | (1.1)
Worldwide | $82,584 |  | 82,059 |  | 0.6 | % | 1.2 |  | (0.6)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries |  |  |  |  |  |  |  |  |
Supplementary Sales Data |  |  |  |  |  |  |  |  |
(Unaudited; Dollars in Millions) | FOURTH QUARTER
|  |  |  |  | Percent Change
| 2020 |  | 2019 |  | Total |  | Operations |  | Currency
Sales to customers by |  |  |  |  |  |  |  |  |
segment of business |  |  |  |  |  |  |  |  |
Consumer Health |  |  |  |  |  |  |  |  |
U.S. | $ | 1,509 |  |  | 1,470 |  |  | 2.7 |  | % | 2.7 |  | — |
International | 2,109 |  |  | 2,097 |  |  | 0.5 |  |  | 1.5 |  |  | (1.0) |
| 3,618 |  |  | 3,567 |  |  | 1.4 |  |  | 2.0 |  |  | (0.6) |
Pharmaceutical |  |  |  |  |  |  |  |  |
U.S. | 7,116 |  |  | 6,169 |  |  | 15.3 |  |  | 15.3 |  | — |
International | 5,152 |  |  | 4,379 |  |  | 17.7 |  |  | 13.5 |  | 4.2 |
| 12,268 |  |  | 10,548 |  |  | 16.3 |  |  | 14.6 |  | 1.7 |
Medical Devices |  |  |  |  |  |  |  |  |
U.S. | 3,184 |  |  | 3,135 |  |  | 1.5 |  |  | 1.5 |  |  | — |
International | 3,405 |  |  | 3,497 |  |  | (2.6) |  |  | (5.5) |  |  | 2.9 |
| 6,589 |  |  | 6,632 |  |  | (0.7) |  |  | (2.2) |  |  | 1.5 |
U.S. | 11,809 |  |  | 10,774 |  |  | 9.6 |  |  | 9.6 |  |  | — |
International | 10,666 |  |  | 9,973 |  |  | 7.0 |  |  | 4.3 |  |  | 2.7 |
Worldwide | $ | 22,475 |  |  | 20,747 |  |  | 8.3 |  | % | 7.1 |  |  | 1.2 |
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries |  |  |  |  |  |  |  |  |
Supplementary Sales Data |  |  |  |  |  |  |  |  |
(Unaudited; Dollars in Millions) | TWELVE MONTHS
|  |  |  |  | Percent Change
| 2020 |  | 2019 |  | Total |  | Operations |  | Currency
Sales to customers by |  |  |  |  |  |  |  |  |
segment of business |  |  |  |  |  |  |  |  |
Consumer Health |  |  |  |  |  |  |  |  |
U.S. | $ | 6,362 |  |  | 5,839 |  | 9.0 | % | 9.0 |  | -
International | 7,691 |  | 8,059 |  | (4.6) |  | (1.3) |  | (3.3)
| 14,053 |  | 13,898 |  | 1.1 |  | 3.0 |  | (1.9)
Pharmaceutical |  |  |  |  |  |  |  |  |
U.S. | 25,735 |  | 23,874 |  | 7.8 |  | 7.8 |  | -
International | 19,837 |  | 18,324 |  | 8.3 |  | 8.8 |  | (0.5)
| 45,572 |  | 42,198 |  | 8.0 |  | 8.2 |  | (0.2)
Medical Devices |  |  |  |  |  |  |  |  |
U.S. | 11,036 |  | 12,384 |  | (10.9) |  | (10.9) |  | -
International | 11,923 |  | 13,579 |  | (12.2) |  | (11.8) |  | (0.4)
| 22,959 |  | 25,963 |  | (11.6) |  | (11.4) |  | (0.2)
U.S. | 43,133 |  | 42,097 |  | 2.5 |  | 2.5 |  | -
International | 39,451 |  | 39,962 |  | (1.3) |  | (0.2) |  | (1.1)
Worldwide | $ | 82,584 |  |  | 82,059 |  | 0.6 | % | 1.2 |  | (0.6)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries |  |  |  |  |  |  |  |  |
Condensed Consolidated Statement of Earnings |  |  |  |  |  |  |  |  |
(Unaudited; in Millions Except Per Share Figures) | FOURTH QUARTER
| 2020 |  | 2019 |  | Percent
|  |  | Percent |  |  |  | Percent |  | Increase
| Amount |  | to Sales |  | Amount |  | to Sales |  | (Decrease)
Sales to customers | $ | 22,475 |  |  | 100.0 |  | $ | 20,747 |  |  | 100.0 |  | 8.3 |
Cost of products sold | 7,814 |  |  | 34.8 |  | 7,134 |  |  | 34.4 |  | 9.5 |
Gross Profit | 14,661 |  |  | 65.2 |  | 13,613 |  |  | 65.6 |  | 7.7 |
Selling, marketing and administrative expenses | 6,457 |  |  | 28.7 |  | 6,039 |  |  | 29.1 |  | 6.9 |
Research and development expense | 4,032 |  |  | 17.9 |  | 3,232 |  |  | 15.6 |  | 24.8 |
In-process research and development | 37 |  |  | 0.2 |  |  | — |  |  | — |  |  |
Interest (income) expense, net | 74 |  |  | 0.3 |  |  | 4 |  |  | 0.0 |  |  |
Other (income) expense, net | 2,354 |  |  | 10.5 |  |  | 16 |  |  | 0.1 |  |  |
Restructuring | 60 |  |  | 0.3 |  | 104 |  |  | 0.5 |  |
Earnings before provision for taxes on income | 1,647 |  |  | 7.3 |  | 4,218 |  |  | 20.3 |  | (61.0) |
Provision for/(Benefit from) taxes on income | (91) |  |  | (0.4) |  | 208 |  |  | 1.0 |  |  | (143.8) |
Net earnings | $ | 1,738 |  |  | 7.7 |  | $ | 4,010 |  |  | 19.3 |  | (56.7) |
Net earnings per share (Diluted) | $ | 0.65 |  |  |  |  | $ | 1.50 |  |  |  |  | (56.7) |
Average shares outstanding (Diluted) | 2,669.2 |  |  |  |  | 2,669.1 |  |  |  |  |
Effective tax rate | (5.5) |  | % |  |  | 4.9 |  | % |  |  |
Adjusted earnings before provision for taxes and net earnings (1) (A) |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income | $ | 5,601 |  |  | 24.9 |  | $ | 5,628 |  |  | 27.1 |  | (0.5) |
Net earnings | $ | 4,965 |  |  | 22.1 |  | $ | 5,027 |  |  | 24.2 |  | (1.2) |
Net earnings per share (Diluted) | $ | 1.86 |  |  |  |  | $ | 1.88 |  |  |  |  | (1.1) |
Effective tax rate | 11.4 |  | % |  |  | 10.7 |  | % |  |  |
(1) See Reconciliation of Non-GAAP Financial Measures. |  |  |  |  |  |  |  |  |
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Johnson & Johnson and Subsidiaries |  |  |  |  |  |  |  |  |
Condensed Consolidated Statement of Earnings |  |  |  |  |  |  |  |  |
(Unaudited; in Millions Except Per Share Figures) | TWELVE MONTHS
| 2020 |  | 2019 |  | Percent
|  |  | Percent |  |  |  | Percent |  | Increase
| Amount |  | to Sales |  | Amount |  | to Sales |  | (Decrease)
Sales to customers | $ | 82,584 |  |  | 100.0 |  | $ | 82,059 |  |  | 100.0 |  | 0.6
Cost of products sold | 28,427 |  | 34.4 |  | 27,556 |  | 33.6 |  | 3.2
Gross Profit | 54,157 |  | 65.6 |  | 54,503 |  | 66.4 |  | (0.6)
Selling, marketing and administrative expenses | 22,084 |  | 26.8 |  | 22,178 |  | 27.0 |  | (0.4)
Research and development expense | 12,159 |  | 14.7 |  | 11,355 |  | 13.8 |  | 7.1
In-process research and development | 181 |  | 0.2 |  | 890 |  | 1.1 |  |
Interest (income) expense, net | 90 |  | 0.1 |  | (39) |  | 0.0 |  |
Other (income) expense, net | 2,899 |  | 3.5 |  | 2,525 |  | 3.1 |  |
Restructuring | 247 |  | 0.3 |  | 266 |  | 0.3 |  |
Earnings before provision for taxes on income | 16,497 |  | 20.0 |  | 17,328 |  | 21.1 |  | (4.8)
Provision for taxes on income | 1,783 |  | 2.2 |  | 2,209 |  | 2.7 |  | (19.3)
Net earnings | $ | 14,714 |  |  | 17.8 |  | $ | 15,119 |  |  | 18.4 |  | (2.7)
Net earnings per share (Diluted) | $ | 5.51 |  |  |  |  | $ | 5.63 |  |  |  |  | (2.1)
Average shares outstanding (Diluted) | 2,670.7 |  |  |  | 2,684.3 |  |  |  |
Effective tax rate | 10.8 | % |  |  | 12.7 | % |  |  |
Adjusted earnings before provision for taxes and net earnings (1) (A) |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income | $ | 25,428 |  |  | 30.8 |  | $ | 28,225 |  |  | 34.4 |  | (9.9)
Net earnings | $ | 21,433 |  |  | 26.0 |  | $ | 23,310 |  |  | 28.4 |  | (8.1)
Net earnings per share (Diluted) | $ | 8.03 |  |  |  |  | $ | 8.68 |  |  |  |  | (7.5)
Effective tax rate | 15.7 | % |  |  | 17.4 | % |  |  |
(1) See Reconciliation of Non-GAAP Financial Measures. |  |  |  |  |  |  |  |  |
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Johnson & Johnson and Subsidiaries |  |  |
Reconciliation of Non-GAAP Financial Measures |  |  |
|  | Fourth Quarter
| (Dollars in Millions Except Per Share Data) | 2020 |  | 2019
| Net Earnings, after tax- as reported | $1,738 |  | $4,010
| Pre-tax Adjustments |  |  |
| Intangible Asset Amortization expense | 1,234 |  | 1,142
| Litigation expense, net | 2,902 |  | 264
| IPR&D | 37 |  | -
| Restructuring related | 85 |  | 251
| Acquisition and Integration related | 14 |  | 90
| Unrealized (gains)/losses on securities | (373) |  | (350)
| Medical Device Regulation 1 | 55 |  | -
| Other | - |  | 13
| Tax Adjustments |  |  |
| Tax impact on special item adjustments 2 | (606) |  | (123)
| Tax legislation and other tax related | (121) |  | (270)
| Adjusted Net Earnings, after tax | $4,965 |  | $5,027
| Average shares outstanding (Diluted) | 2,669.2 |  | 2,669.1
| Adjusted net earnings per share (Diluted) | $1.86 |  | $1.88
| Operational adjusted net earnings per share (Diluted) | $1.82 |  |
| Notes: |  |  |
1 | European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
2 | The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
| Prior year amounts have been reclassified to conform to current year disclosure

Johnson & Johnson and Subsidiaries |  |  |
Reconciliation of Non-GAAP Financial Measures |  |  |
|  | Twelve Months Ended
| (Dollars in Millions Except Per Share Data) | 2020 |  | 2019
| Net Earnings, after tax- as reported | $14,714 |  | $15,119
| Pre-tax Adjustments |  |  |
| Intangible Asset Amortization expense | 4,660 |  | 4,528
| Litigation expense, net | 5,112 |  | 5,096
| IPR&D | 181 |  | 890
| Restructuring related | 448 |  | 611
| Acquisition and Integration related ¹ | (1,073) |  | 319
| Unrealized (gains)/losses on securities | (547) |  | (567)
| Medical Device Regulation 2 | 144 |  | -
| Other | 6 |  | 20
| Tax Adjustments |  |  |
| Tax impact on special item adjustments 3 | (1,608) |  | (1,977)
| Tax legislation and other tax related | (604) |  | (729)
| Adjusted Net Earnings, after tax | $21,433 |  | $23,310
| Average shares outstanding (Diluted) | 2,670.7 |  | 2,684.3
| Adjusted net earnings per share (Diluted) | $8.03 |  | $8.68
| Operational adjusted net earnings per share (Diluted) | $8.00 |  |
| Notes: |  |  |
1 | Acquisition and integration related costs for 2020 primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2 | European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
3 | The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
| Prior year amounts have been reclassified to conform to current year disclosure

Johnson & Johnson and Subsidiaries |  |  |  |  |  |  |  |
Reconciliation of Non-GAAP Financial Measure |  |  |  |  |  |  |  |
Adjusted Operational Sales Growth (A)
Fourth Quarter 2020 Actual vs. 2019 Actual
Segments
|  | Consumer Health |  | Pharmaceutical |  | Medical Devices |  | Total
WW As Reported |  | 1.4 | % |  | 16.3 | % |  | (0.7) | % |  | 8.3 | %
U.S. |  | 2.7 | % |  | 15.3 | % |  | 1.5 | % |  | 9.6 | %
International |  | 0.5 | % |  | 17.7 | % |  | (2.6) | % |  | 7.0 | %
WW Currency |  | (0.6) |  | 1.7 |  | 1.5 |  | 1.2
U.S. |  | — |  | — |  | — |  | —
International |  | (1.0) |  | 4.2 |  | 2.9 |  | 2.7
WW Operational |  | 2.0 | % |  | 14.6 | % |  | (2.2) | % |  | 7.1 | %
U.S. |  | 2.7 | % |  | 15.3 | % |  | 1.5 | % |  | 9.6 | %
International |  | 1.5 | % |  | 13.5 | % |  | (5.5) | % |  | 4.3 | %
General Surgery |  |  |  |  |  |  |  |
Advanced Sterilization Products |  |  |  |  |  | 0.6 |  | 0.2
U.S. |  |  |  |  |  | 0.0 |  | 0.0
International |  |  |  |  |  | 1.0 |  | 0.4
All Other Acquisitions and Divestitures |  | 0.1 |  | 0.0 |  | 0.1 |  | 0.1
U.S. |  | 0.1 |  | (0.1) |  | 0.2 |  | 0.0
International |  | 0.1 |  | 0.2 |  | 0.0 |  | 0.1
WW Adjusted Operational |  | 2.1 | % |  | 14.6 | % |  | (1.5) | % |  | 7.3 | %
U.S. |  | 2.8 | % |  | 15.2 | % |  | 1.7 | % |  | 9.6 | %
International |  | 1.6 | % |  | 13.7 | % |  | (4.4) | % |  | 4.8 | %
Note: Percentages are based on actual, non-rounded figures and may not sum |  |
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

Johnson & Johnson and Subsidiaries |  |  |  |  |  |  |  |
Reconciliation of Non-GAAP Financial Measure |  |  |  |  |  |  |  |
Adjusted Operational Sales Growth (A)
Twelve Months 2020 Actual vs. 2019 Actual
Segments
|  | Consumer Health |  | Pharmaceutical |  | Medical Devices |  | Total
WW As Reported |  | 1.1 | % |  | 8.0 | % |  | (11.6) | % |  | 0.6 | %
U.S. |  | 9.0 | % |  | 7.8 | % |  | (10.9) | % |  | 2.5 | %
International |  | (4.6) | % |  | 8.3 | % |  | (12.2) | % |  | (1.3) | %
WW Currency |  | (1.9) |  | (0.2) |  | (0.2) |  | (0.6)
U.S. |  | — |  | — |  | — |  | —
International |  | (3.3) |  | (0.5) |  | (0.4) |  | (1.1)
WW Operational |  | 3.0 | % |  | 8.2 | % |  | (11.4) | % |  | 1.2 | %
U.S. |  | 9.0 | % |  | 7.8 | % |  | (10.9) | % |  | 2.5 | %
International |  | (1.3) | % |  | 8.8 | % |  | (11.8) | % |  | (0.2) | %
Skin Health / Beauty |  |  |  |  |  |  |  |
Dr. Ci Labo - Japan |  | (0.1) |  |  |  |  |  | 0.0
U.S. |  | 0.0 |  |  |  |  |  | 0.0
International |  | (0.2) |  |  |  |  |  | 0.0
General Surgery |  |  |  |  |  |  |  |
Advanced Sterilization Products |  |  |  |  |  | 0.8 |  | 0.3
U.S. |  |  |  |  |  | 0.6 |  | 0.2
International |  |  |  |  |  | 1.0 |  | 0.4
Baby Care |  |  |  |  |  |  |  |
Baby Center |  | 0.2 |  |  |  |  |  | 0.0
U.S. |  | 0.5 |  |  |  |  |  | 0.1
International |  | 0.0 |  |  |  |  |  | 0.0
All Other Acquisitions and Divestitures |  | 0.0 |  | 0.2 |  | 0.0 |  | 0.1
U.S. |  | 0.0 |  | 0.0 |  | 0.0 |  | 0.0
International |  | (0.1) |  | 0.3 |  | 0.0 |  | 0.1
WW Adjusted Operational |  | 3.1 | % |  | 8.4 | % |  | (10.5) | % |  | 1.5 | %
U.S. |  | 9.5 | % |  | 7.8 | % |  | (10.2) | % |  | 2.8 | %
International |  | (1.5) | % |  | 9.1 | % |  | (10.9) | % |  | 0.2 | %
Note: Percentages are based on actual, non-rounded figures and may not sum |  |
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | FOURTH QUARTER
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
CONSUMER HEALTH SEGMENT (2) (3) |  |  |  |  |  |  |  |
OTC |  |  |  |  |  |  |  |  |
US |  | $ | 543 |  | 542 |  | 0.1 | % | 0.1 | % | — | %
Intl |  |  | 642 |  | 653 |  | (1.7) |  | (2.9) |  | 1.2 |
WW |  |  | 1,185 |  | 1,195 |  | (0.8) |  | (1.5) |  | 0.7 |
SKIN HEALTH / BEAUTY (4) |  |  |  |  |  |  |  |  |
US |  |  | 583 |  | 582 |  | 0.2 |  | 0.2 |  | — |
Intl |  |  | 594 |  | 568 |  | 4.6 |  | 5.0 |  | (0.4) |
WW |  |  | 1,177 |  |  | 1,150 |  | 2.4 |  | 2.6 |  | (0.2) |
ORAL CARE |  |  |  |  |  |  |  |  |
US |  |  | 173 |  | 159 |  | 8.3 |  | 8.3 |  | — |
Intl |  |  | 264 |  | 233 |  | 13.5 |  | 14.5 |  | (1.0) |
WW |  |  | 437 |  |  | 393 |  |  | 11.4 |  | 12.0 |  | (0.6) |
BABY CARE |  |  |  |  |  |  |  |  |
US |  |  | 97 |  | 85 |  | 14.3 |  | 14.3 |  | — |
Intl |  |  | 310 |  | 336 |  | (7.8) |  | (3.6) |  | (4.2) |
WW |  |  | 407 |  |  | 421 |  |  | (3.4) |  | 0.0 |  | (3.4) |
WOMEN'S HEALTH |  |  |  |  |  |  |  |  |
US |  |  | 3 |  | 3 |  | 11.8 |  | 11.8 |  | — |
Intl |  |  | 234 |  | 250 |  | (6.5) |  | (3.1) |  | (3.4) |
WW |  |  | 237 |  | 253 |  | (6.3) |  | (2.9) |  | (3.4) |
WOUND CARE / OTHER |  |  |  |  |  |  |  |  |
US |  |  | 110 |  | 98 |  | 11.8 |  | 11.8 |  | — |
Intl |  |  | 65 |  | 57 |  | 12.4 |  | 13.0 |  | (0.6) |
WW |  |  | 175 |  | 155 |  | 12.0 |  | 12.2 |  | (0.2) |
TOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |
US |  |  | 1,509 |  |  | 1,470 |  |  | 2.7 |  | 2.7 |  | — |
Intl |  |  | 2,109 |  |  | 2,097 |  |  | 0.5 |  | 1.5 |  | (1.0) |
WW |  | $ | 3,618 |  |  | 3,567 |  |  | 1.4 | % | 2.0 | % | (0.6) | %
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | FOURTH QUARTER
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
PHARMACEUTICAL SEGMENT (2) (5) |  |  |  |  |  |
IMMUNOLOGY |  |  |  |  |  |  |  |  |
US |  | $ | 2,845 |  | 2,517 |  | 13.0 | % | 13.0 | % | — | %
Intl |  |  | 1,261 |  | 1,005 |  | 25.4 |  | 21.1 |  | 4.3 |
WW |  |  | 4,105 |  | 3,522 |  | 16.6 |  | 15.3 |  | 1.3 |
REMICADE |  |  |  |  |  |  |  |  |
US |  |  | 656 |  | 755 |  | (13.1) |  | (13.1) |  | — |
US Exports (6) |  |  | 25 |  | 68 |  | (62.4) |  | (62.4) |  | — |
Intl |  |  | 220 |  | 212 |  | 3.3 |  | 2.7 |  | 0.6 |
WW |  |  | 901 |  | 1,035 |  | (12.9) |  | (13.1) |  | 0.2 |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |
US |  |  | 315 |  | 302 |  | 4.4 |  | 4.4 |  | — |
Intl |  |  | 261 |  | 213 |  | 22.9 |  | 18.8 |  | 4.1 |
WW |  |  | 576 |  | 515 |  | 12.1 |  | 10.4 |  | 1.7 |
STELARA |  |  |  |  |  |  |  |  |
US |  |  | 1,572 |  | 1,194 |  | 31.6 |  | 31.6 |  | — |
Intl |  |  | 672 |  | 506 |  | 32.7 |  | 27.2 |  | 5.5 |
WW |  |  | 2,244 |  | 1,700 |  | 31.9 |  | 30.3 |  | 1.6 |
TREMFYA |  |  |  |  |  |  |  |  |
US |  |  | 276 |  |  | 199 |  |  | 39.1 |  | 39.1 |  | — |
Intl |  |  | 105 |  |  | 71 |  |  | 48.1 |  | 40.0 |  | 8.1 |
WW |  |  | 382 |  |  | 270 |  |  | 41.5 |  | 39.3 |  | 2.2 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |
US |  |  | — |  |  | — |  |  | — |  | — |  | — |
Intl |  |  | 2 |  | 2 |  | (19.7) |  | (14.5) |  | (5.2) |
WW |  |  | 2 |  | 2 |  | (19.7) |  | (14.5) |  | (5.2) |
INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |
US |  |  | 470 |  | 435 |  | 7.9 |  | 7.9 |  | — |
Intl |  |  | 442 |  | 430 |  | 2.8 |  | (2.6) |  | 5.4 |
WW |  |  | 912 |  | 866 |  | 5.4 |  | 2.7 |  | 2.7 |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |
US |  |  | 11 |  |  | 14 |  |  | (17.9) |  | (17.9) |  | — |
Intl |  |  | 236 |  |  | 209 |  |  | 13.4 |  | 6.2 |  | 7.2 |
WW |  |  | 248 |  |  | 222 |  |  | 11.4 |  | 4.7 |  | 6.7 |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |
US |  |  | 433 |  | 390 |  | 11.1 |  | 11.1 |  | — |
Intl |  |  | 136 |  | 155 |  | (12.4) |  | (17.1) |  | 4.7 |
WW |  |  | 569 |  | 544 |  | 4.4 |  | 3.1 |  | 1.3 |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |
US |  |  | 25 |  | 32 |  | (20.4) |  | (20.4) |  | — |
Intl |  |  | 71 |  | 67 |  | 5.2 |  | 3.3 |  | 1.9 |
WW |  |  | 96 |  | 99 |  | (3.0) |  | (4.3) |  | 1.3 |
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | FOURTH QUARTER
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued) |  |  |  |  |  |
NEUROSCIENCE |  |  |  |  |  |  |  |  |
US |  | $ | 806 |  | 747 |  | 7.9 | % | 7.9 | % | — | %
Intl |  |  | 892 |  | 819 |  | 9.0 |  | 6.2 |  | 2.8
WW |  |  | 1,698 |  | 1,566 |  | 8.5 |  | 7.0 |  | 1.5
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |
US |  |  | 33 |  | 37 |  | (9.7) | (9.7) | —
Intl |  |  | 120 |  | 115 |  | 4.2 |  | 1.4 |  | 2.8
WW |  |  | 153 |  | 152 |  | 0.9 |  | (1.2) |  | 2.1
INVEGA SUSTENNA / XEPLION / INVEGA |  |  |  |  |
TRINZA / TREVICTA |  |  |  |  |  |  |  |  |
US |  |  | 610 |  | 564 |  | 8.1 |  | 8.1 |  | —
Intl |  |  | 355 |  | 308 |  |  | 15.7 |  | 10.8 |  | 4.9
WW |  |  | 965 |  | 871 |  | 10.8 |  | 9.0 |  | 1.8
RISPERDAL CONSTA |  |  |  |  |  |  |  |  |
US |  |  | 76 |  | 77 |  | (2.5) | (2.5) | —
Intl |  |  | 92 |  | 82 |  | 11.0 |  | 7.7 |  | 3.3
WW |  |  | 167 |  | 160 |  | 4.4 |  | 2.7 |  | 1.7
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |
US |  |  | 88 |  | 70 |  | 27.4 |  | 27.4 |  | —
Intl |  |  | 326 |  | 314 |  | 3.7 |  | 3.1 |  | 0.6
WW |  |  | 414 |  | 383 |  | 8.0 |  | 7.5 |  | 0.5
ONCOLOGY |  |  |  |  |  |  |  |  |
US |  |  | 1,469 |  | 1,153 |  | 27.4 |  | 27.4 |  | —
Intl |  |  | 1,965 |  |  | 1,563 |  |  | 25.7 |  | 20.9 |  | 4.8
WW |  |  | 3,434 |  | 2,716 |  | 26.4 |  | 23.7 |  | 2.7
DARZALEX |  |  |  |  |  |  |  |  |
US |  |  | 692 |  |  | 444 |  |  | 55.6 |  | 55.6 |  | —
Intl |  |  | 561 |  |  | 385 |  |  | 45.4 |  | 41.3 |  | 4.1
WW |  |  | 1,253 |  |  | 830 |  |  | 50.9 |  | 49.0 |  | 1.9
ERLEADA |  |  |  |  |  |  |  |  |
US |  |  | 176 |  |  | 103 |  |  | 70.8 |  | 70.8 |  | —
Intl |  |  | 64 |  |  | 13 |  |  | * | * | *
WW |  |  | 241 |  |  | 116 |  |  | * | * | *
IMBRUVICA |  |  |  |  |  |  |  |  |
US |  |  | 492 |  |  | 392 |  |  | 25.8 |  | 25.8 |  | —
Intl |  |  | 625 |  |  | 483 |  |  | 29.3 |  | 24.8 |  | 4.5
WW |  |  | 1,117 |  |  | 875 |  |  | 27.8 |  | 25.3 |  | 2.5
VELCADE |  |  |  |  |  |  |  |  |
US |  |  | — |  |  | — |  |  | — | — | —
Intl |  |  | 97 |  | 115 |  | (15.2) | (18.5) | 3.3
WW |  |  | 97 |  | 115 |  | (15.2) | (18.5) | 3.3
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |
US |  |  | 89 |  | 194 |  |  | (54.3) | (54.3) | —
Intl |  |  | 533 |  | 483 |  | 10.2 |  | 4.3 |  | 5.9
WW |  |  | 622 |  | 677 |  | (8.3) | (12.5) | 4.2
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |
US |  |  | 20 |  |  | 19 |  |  | 2.6 |  | 2.6 |  | —
Intl |  |  | 86 |  | 84 |  | 1.5 |  | (2.1) | 3.6
WW |  |  | 105 |  | 104 |  | 1.7 |  | (1.2) | 2.9
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | FOURTH QUARTER
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued) |  |  |  |
PULMONARY HYPERTENSION |  |  |  |  |  |
US |  | $ | 592 |  |  | 388 |  |  | 52.5 | % | 52.5 | % | — | %
Intl |  |  | 273 |  |  | 235 |  |  | 16.8 |  | 12.5 |  | 4.3 |
WW |  |  | 865 |  |  | 623 |  |  | 39.0 |  | 37.4 |  | 1.6 |
OPSUMIT |  |  |  |  |  |  |  |  |
US |  |  | 279 |  |  | 185 |  |  | 52.1 |  | 52.1 |  | — |
Intl |  |  | 173 |  |  | 143 |  |  | 21.2 |  | 16.9 |  | 4.3 |
WW |  |  | 452 |  |  | 326 |  |  | 38.6 |  | 36.7 |  | 1.9 |
UPTRAVI |  |  |  |  |  |  |  |  |
US |  |  | 263 |  |  | 178 |  |  | 48.2 |  | 48.2 |  | — |
Intl |  |  | 38 |  |  | 30 |  |  | 25.5 |  | 20.1 |  | 5.4 |
WW |  |  | 301 |  |  | 208 |  |  | 44.9 |  | 44.1 |  | 0.8 |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |
US |  |  | 49 |  |  | 26 |  |  | 84.9 |  | 84.9 |  | — |
Intl |  |  | 63 |  |  | 62 |  |  | 2.4 |  | (1.2) |  | 3.6 |
WW |  |  | 112 |  |  | 88 |  |  | 26.6 |  | 24.1 |  | 2.5 |
CARDIOVASCULAR / METABOLISM / OTHER |  |  |  |  |  |
US |  |  | 935 |  |  | 930 |  |  | 0.6 |  | 0.6 |  | — |
Intl |  |  | 317 |  |  | 327 |  |  | (2.6) |  | (5.4) |  | 2.8 |
WW |  |  | 1,253 |  |  | 1,256 |  |  | (0.2) |  | (1.0) |  | 0.8 |
XARELTO |  |  |  |  |  |  |  |  |
US |  |  | 629 |  |  | 609 |  |  | 3.1 |  | 3.1 |  | — |
Intl |  |  | — |  |  | — |  |  | — |  | — |  | — |
WW |  |  | 629 |  |  | 609 |  |  | 3.1 |  | 3.1 |  | — |
INVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |
US |  |  | 159 |  |  | 125 |  |  | 27.7 |  | 27.7 |  | — |
Intl |  |  | 58 |  |  | 52 |  |  | 11.5 |  | 8.9 |  | 2.6 |
WW |  |  | 217 |  |  | 177 |  |  | 22.9 |  | 22.1 |  | 0.8 |
PROCRIT / EPREX |  |  |  |  |  |  |  |  |
US |  |  | 62 |  |  | 118 |  |  | (46.9) |  | (46.9) |  | — |
Intl |  |  | 66 |  |  | 65 |  |  | 2.0 |  | (1.1) |  | 3.1 |
WW |  |  | 129 |  |  | 183 |  |  | (29.5) |  | (30.6) |  | 1.1 |
OTHER |  |  |  |  |  |  |  |  |
US |  |  | 85 |  |  | 78 |  |  | 9.4 |  | 9.4 |  | — |
Intl |  |  | 194 |  |  | 209 |  |  | (7.6) |  | (10.3) |  | 2.7 |
WW |  |  | 278 |  |  | 286 |  |  | (3.0) |  | (5.0) |  | 2.0 |
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |
US |  |  | 7,116 |  |  | 6,169 |  |  | 15.3 |  | 15.3 |  | — |
Intl |  |  | 5,152 |  |  | 4,379 |  |  | 17.7 |  | 13.5 |  | 4.2 |
WW |  | $ | 12,268 |  |  | 10,548 |  |  | 16.3 |  | 14.6 |  | 1.7 | %
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | FOURTH QUARTER
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
MEDICAL DEVICES SEGMENT (2) (5) |  |  |  |  |  |
INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |
US |  | $ | 433 |  |  | 377 |  |  | 14.8 | % | 14.8 | % | — | %
Intl |  |  | 460 |  |  | 398 |  | 15.7 |  | 10.8 |  | 4.9 |
WW |  |  | 893 |  |  | 774 |  | 15.3 |  | 12.8 |  | 2.5 |
ORTHOPAEDICS |  |  |  |  |  |  |  |  |
US |  |  | 1,352 |  |  | 1,369 |  |  | (1.3) |  | (1.3) |  | — |
Intl |  |  | 839 |  |  | 904 |  |  | (7.3) |  | (11.3) |  | 4.0 |
WW |  |  | 2,191 |  |  | 2,273 |  |  | (3.7) |  | (5.3) |  | 1.6 |
HIPS |  |  |  |  |  |  |  |  |
US |  |  | 229 |  |  | 230 |  |  | (0.7) |  | (0.7) |  | — |
Intl |  |  | 143 |  |  | 147 |  |  | (2.2) |  | (5.8) |  | 3.6 |
WW |  |  | 372 |  |  | 377 |  |  | (1.3) |  | (2.7) |  | 1.4 |
KNEES |  |  |  |
US |  |  | 216 |  |  | 239 |  |  | (9.5) |  | (9.5) |  | — |
Intl |  |  | 129 |  |  | 156 |  |  | (17.2) |  | (20.6) |  | 3.4 |
WW |  |  | 345 |  |  | 395 |  |  | (12.5) |  | (13.9) |  | 1.4 |
TRAUMA |  |  |  |  |  |  |  |  |
US |  |  | 454 |  |  | 413 |  |  | 10.0 |  | 10.0 |  | — |
Intl |  |  | 268 |  |  | 273 |  |  | (2.0) |  | (6.2) |  | 4.2 |
WW |  |  | 722 |  |  | 686 |  |  | 5.2 |  | 3.6 |  | 1.6 |
SPINE, SPORTS & OTHER (7) |  |
US |  |  | 453 |  |  | 488 |  |  | (7.1) |  | (7.1) |  | — |
Intl |  |  | 299 |  |  | 329 |  |  | (9.2) |  | (13.6) |  | 4.4 |
WW |  |  | 752 |  |  | 817 |  |  | (7.9) |  | (9.7) |  | 1.8 |
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | FOURTH QUARTER
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
MEDICAL DEVICES SEGMENT (2) (5) (Continued) |  |  |  |  |  |
SURGERY |  |  |  |  |  |
US |  | $ | 1,002 |  |  | 961 |  |  | 4.3 | % | 4.3 | % | — | %
Intl |  |  | 1,427 |  |  | 1,481 |  |  | (3.7) |  | (5.9) |  | 2.2 |
WW |  |  | 2,429 |  |  | 2,442 |  |  | (0.5) |  | (1.9) |  | 1.4 |
ADVANCED |  |  |  |  |  |  |  |  |
US |  |  | 456 |  |  | 428 |  |  | 6.5 |  | 6.5 |  | — |
Intl |  |  | 660 |  |  | 647 |  |  | 2.1 |  | (0.9) |  | 3.0 |
WW |  |  | 1,116 |  |  | 1,076 |  |  | 3.8 |  | 2.0 |  | 1.8 |
GENERAL |  |  |  |  |  |  |  |  |
US |  |  | 546 |  |  | 534 |  |  | 2.5 |  | 2.5 |  | — |
Intl |  |  | 767 |  |  | 834 |  |  | (8.1) |  | (9.8) |  | 1.7 |
WW |  |  | 1,312 |  |  | 1,366 |  |  | (4.0) |  | (5.0) |  | 1.0 |
VISION |  |  |  |
US |  |  | 397 |  |  | 428 |  |  | (7.3) |  | (7.3) |  | — |
Intl |  |  | 679 |  |  | 713 |  |  | (4.7) |  | (6.2) |  | 1.5 |
WW |  |  | 1,076 |  |  | 1,141 |  |  | (5.7) |  | (6.6) |  | 0.9 |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |
US |  |  | 289 |  |  | 311 |  |  | (7.4) |  | (7.4) |  | — |
Intl |  |  | 507 |  |  | 522 |  |  | (2.7) |  | (4.1) |  | 1.4 |
WW |  |  | 796 |  |  | 833 |  |  | (4.4) |  | (5.3) |  | 0.9 |
SURGICAL |  |  |  |  |  |  |  |  |
US |  |  | 108 |  |  | 117 |  |  | (7.1) |  | (7.1) |  | — |
Intl |  |  | 172 |  |  | 191 |  |  | (10.3) |  | (12.0) |  | 1.7 |
WW |  |  | 280 |  |  | 309 |  |  | (9.1) |  | (10.1) |  | 1.0 |
TOTAL MEDICAL DEVICES |  |
US |  |  | 3,184 |  |  | 3,135 |  |  | 1.5 |  | 1.5 |  | — |
Intl |  |  | 3,405 |  |  | 3,497 |  |  | (2.6) |  | (5.5) |  | 2.9 |
WW |  | $ | 6,589 |  |  | 6,632 |  |  | (0.7) | % | (2.2) | % | 1.5 | %
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | TWELVE MONTHS
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
CONSUMER HEALTH SEGMENT (2) (3) |  |  |  |  |  |  |  |
OTC |  |  |  |  |  |  |  |  |
US |  | $ | 2,460 |  |  | 2,010 |  |  | 22.4 | % | 22.4 | % | — | %
Intl |  |  | 2,364 |  |  | 2,434 |  |  | (2.9) |  | (1.2) |  | (1.7) |
WW |  |  | 4,824 |  |  | 4,444 |  |  | 8.5 |  | 9.4 |  | (0.9) |
SKIN HEALTH / BEAUTY (4) |  |  |  |  |  |  |  |  |
US |  |  | 2,350 |  |  | 2,392 |  |  | (1.7) |  | (1.7) |  | —
Intl |  |  | 2,100 |  |  | 2,201 |  |  | (4.6) |  | (2.3) |  | (2.3) |
WW |  |  | 4,450 |  |  | 4,593 |  |  | (3.1) |  | (2.0) |  | (1.1) |
ORAL CARE |  |  |  |  |  |  |  |  |
US |  |  | 683 |  |  | 621 |  |  | 9.9 |  | 9.9 |  | —
Intl |  |  | 958 |  |  | 906 |  |  | 5.7 |  | 9.6 |  | (3.9) |
WW |  |  | 1,641 |  |  | 1,528 |  |  | 7.4 |  | 9.7 |  | (2.3) |
BABY CARE |  |  |  |  |  |  |  |  |
US |  |  | 376 |  |  | 362 |  |  | 3.7 |  | 3.7 |  | —
Intl |  |  | 1,141 |  |  | 1,313 |  |  | (13.1) |  | (7.3) |  | (5.8) |
WW |  |  | 1,517 |  |  | 1,675 |  |  | (9.4) |  | (4.9) |  | (4.5) |
WOMEN'S HEALTH |  |  |  |  |  |  |  |  |
US |  |  | 13 |  |  | 12 |  |  | 8.2 |  | 8.2 |  | —
Intl |  |  | 888 |  |  | 974 |  |  | (8.8) |  | (2.9) |  | (5.9) |
WW |  |  | 901 |  |  | 986 |  |  | (8.6) |  | (2.7) |  | (5.9) |
WOUND CARE / OTHER |  |  |  |  |  |  |  |  |
US |  |  | 480 |  |  | 441 |  |  | 8.9 |  | 8.9 |  | —
Intl |  |  | 240 |  |  | 230 |  |  | 4.1 |  | 7.3 |  | (3.2) |
WW |  |  | 720 |  |  | 671 |  |  | 7.2 |  | 8.3 |  | (1.1) |
TOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |
US |  |  | 6,362 |  |  | 5,839 |  |  | 9.0 |  | 9.0 |  | —
Intl |  |  | 7,691 |  |  | 8,059 |  |  | (4.6) |  | (1.3) |  | (3.3) |
WW |  | $ | 14,053 |  |  | 13,898 |  |  | 1.1 | % | 3.0 | % | (1.9) | %
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | TWELVE MONTHS
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
PHARMACEUTICAL SEGMENT (2) (5) |  |  |  |  |  |
IMMUNOLOGY |  |  |  |  |  |  |  |  |
US |  | $ | 10,175 |  |  | 9,641 |  |  | 5.5 | % | 5.5 | % | — | %
Intl |  |  | 4,880 |  |  | 4,309 |  |  | 13.2 |  | 14.0 |  | (0.8)
WW |  |  | 15,055 |  |  | 13,950 |  |  | 7.9 |  | 8.2 |  | (0.3)
REMICADE |  |  |  |  |  |  |  |  |
US |  |  | 2,508 |  |  | 3,079 |  |  | (18.5) |  | (18.5) |  | —
US Exports (6) |  |  | 346 |  |  | 294 |  |  | 18.0 |  | 18.0 |  | —
Intl |  |  | 893 |  |  | 1,007 |  |  | (11.4) |  | (8.6) |  | (2.8)
WW |  |  | 3,747 |  |  | 4,380 |  |  | (14.4) |  | (13.8) |  | (0.6)
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |
US |  |  | 1,155 |  |  | 1,159 |  |  | (0.3) |  | (0.3) |  | —
Intl |  |  | 1,088 |  |  | 1,029 |  |  | 5.8 |  | 7.0 |  | (1.2)
WW |  |  | 2,243 |  |  | 2,188 |  |  | 2.6 |  | 3.1 |  | (0.5)
STELARA |  |  |  |  |  |  |  |  |
US |  |  | 5,240 |  |  | 4,346 |  |  | 20.6 |  | 20.6 |  | —
Intl |  |  | 2,467 |  |  | 2,015 |  |  | 22.4 |  | 22.2 |  | 0.2
WW |  |  | 7,707 |  |  | 6,361 |  |  | 21.1 |  | 21.1 |  | 0.0
TREMFYA |  |  |  |  |  |  |  |  |
US |  |  | 926 |  |  | 764 |  |  | 21.3 |  | 21.3 |  | —
Intl |  |  | 421 |  |  | 248 |  |  | 69.9 |  | 67.9 |  | 2.0
WW |  |  | 1,347 |  |  | 1,012 |  |  | 33.2 |  | 32.7 |  | 0.5
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |
US |  |  | — |  |  | — |  |  | — | — | —
Intl |  |  | 11 |  |  | 10 |  |  | 6.4 |  | 12.8 |  | (6.4)
WW |  |  | 11 |  |  | 10 |  |  | 6.4 |  | 12.8 |  | (6.4)
INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |
US |  |  | 1,735 |  |  | 1,597 |  |  | 8.6 |  | 8.6 |  | —
Intl |  |  | 1,839 |  |  | 1,815 |  |  | 1.3 |  | 2.2 |  | (0.9)
WW |  |  | 3,574 |  |  | 3,413 |  |  | 4.7 |  | 5.2 |  | (0.5)
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |
US |  |  | 44 |  |  | 50 |  |  | (11.2) |  | (11.2) |  | —
Intl |  |  | 920 |  |  | 812 |  |  | 13.3 |  | 11.9 |  | 1.4
WW |  |  | 964 |  |  | 861 |  |  | 11.9 |  | 10.5 |  | 1.4
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |
US |  |  | 1,587 |  |  | 1,422 |  |  | 11.6 |  | 11.6 |  | —
Intl |  |  | 597 |  |  | 689 |  |  | (13.4) |  | (10.7) |  | (2.7)
WW |  |  | 2,184 |  |  | 2,110 |  |  | 3.5 |  | 4.4 |  | (0.9)
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |
US |  |  | 104 |  |  | 126 |  |  | (17.6) |  | (17.6) |  | —
Intl |  |  | 323 |  |  | 315 |  |  | 2.6 |  | 5.6 |  | (3.0)
WW |  |  | 427 |  |  | 441 |  |  | (3.2) |  | (1.0) |  | (2.2)
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | TWELVE MONTHS
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued) |  |  |  |  |  |
NEUROSCIENCE |  |  |  |  |  |  |  |  |
US |  | $ | 3,091 |  |  | 2,919 |  |  | 5.9 | % | 5.9 | % | — | %
Intl |  |  | 3,457 |  |  | 3,409 |  |  | 1.4 |  | 2.2 |  | (0.8)
WW |  |  | 6,548 |  |  | 6,328 |  |  | 3.5 |  | 3.9 |  | (0.4)
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |
US |  |  | 183 |  |  | 233 |  |  | (21.4) |  | (21.4) |  | —
Intl |  |  | 439 |  |  | 463 |  |  | (5.1) |  | (4.5) |  | (0.6)
WW |  |  | 622 |  |  | 696 |  |  | (10.6) |  | (10.2) |  | (0.4)
INVEGA SUSTENNA / XEPLION / INVEGA |  |  |  |  |
TRINZA / TREVICTA |  |  |  |  |  |  |  |  |
US |  |  | 2,314 |  |  | 2,107 |  |  | 9.8 |  | 9.8 |  | —
Intl |  |  | 1,339 |  |  | 1,224 |  |  | 9.4 |  | 9.1 |  | 0.3
WW |  |  | 3,653 |  |  | 3,330 |  |  | 9.7 |  | 9.6 |  | 0.1
RISPERDAL CONSTA |  |  |  |  |  |  |  |  |
US |  |  | 296 |  |  | 314 |  |  | (5.9) |  | (5.9) |  | —
Intl |  |  | 346 |  |  | 374 |  |  | (7.5) |  | (6.9) |  | (0.6)
WW |  |  | 642 |  |  | 688 |  |  | (6.8) |  | (6.4) |  | (0.4)
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |
US |  |  | 298 |  |  | 266 |  |  | 12.4 |  | 12.4 |  | —
Intl |  |  | 1,334 |  |  | 1,349 |  |  | (1.1) |  | 0.7 |  | (1.8)
WW |  |  | 1,632 |  |  | 1,614 |  |  | 1.1 |  | 2.6 |  | (1.5)
ONCOLOGY |  |  |  |  |  |  |  |  |
US |  |  | 5,092 |  |  | 4,299 |  |  | 18.5 |  | 18.5 |  | —
Intl |  |  | 7,275 |  |  | 6,393 |  |  | 13.8 |  | 14.0 |  | (0.2)
WW |  |  | 12,367 |  |  | 10,692 |  |  | 15.7 |  | 15.8 |  | (0.1)
DARZALEX |  |  |  |  |  |  |  |  |
US |  |  | 2,232 |  |  | 1,567 |  |  | 42.4 |  | 42.4 |  | —
Intl |  |  | 1,958 |  |  | 1,430 |  |  | 36.9 |  | 38.0 |  | (1.1)
WW |  |  | 4,190 |  |  | 2,998 |  |  | 39.8 |  | 40.3 |  | (0.5)
ERLEADA |  |  |  |  |  |  |  |  |
US |  |  | 583 |  |  | 297 |  |  | 96.1 |  | 96.1 |  | —
Intl |  |  | 176 |  |  | 35 |  |  | * | * | *
WW |  |  | 760 |  |  | 332 |  |  | * | * | *
IMBRUVICA |  |  |  |  |  |  |  |  |
US |  |  | 1,821 |  |  | 1,555 |  |  | 17.1 |  | 17.1 |  | —
Intl |  |  | 2,307 |  |  | 1,856 |  |  | 24.3 |  | 25.1 |  | (0.8)
WW |  |  | 4,128 |  |  | 3,411 |  |  | 21.0 |  | 21.5 |  | (0.5)
VELCADE |  |  |  |  |  |  |  |  |
US |  |  | — |  |  | — |  |  | — | — | —
Intl |  |  | 408 |  |  | 751 |  |  | (45.7) |  | (45.8) |  | 0.1
WW |  |  | 408 |  |  | 751 |  |  | (45.7) |  | (45.8) |  | 0.1
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |
US |  |  | 373 |  |  | 810 |  |  | (54.0) |  | (54.0) |  | —
Intl |  |  | 2,097 |  |  | 1,985 |  |  | 5.6 |  | 4.7 |  | 0.9
WW |  |  | 2,470 |  |  | 2,795 |  |  | (11.6) |  | (12.3) |  | 0.7
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |
US |  |  | 83 |  |  | 70 |  |  | 19.2 |  | 19.2 |  | —
Intl |  |  | 330 |  |  | 336 |  |  | (1.9) |  | (1.4) |  | (0.5)
WW |  |  | 413 |  |  | 407 |  |  | 1.7 |  | 2.2 |  | (0.5)
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | TWELVE MONTHS
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued) |  |  |  |
PULMONARY HYPERTENSION |  |  |  |  |  |
US |  | $ | 2,133 |  |  | 1,684 |  |  | 26.6 | % | 26.6 | % | — | %
Intl |  |  | 1,015 |  |  | 939 |  |  | 8.2 |  | 8.0 |  | 0.2
WW |  |  | 3,148 |  |  | 2,623 |  |  | 20.0 |  | 20.0 |  | 0.0
OPSUMIT |  |  |  |  |  |  |  |  |
US |  |  | 1,008 |  |  | 766 |  |  | 31.7 |  | 31.7 |  | —
Intl |  |  | 631 |  |  | 562 |  |  | 12.3 |  | 12.3 |  | 0.0
WW |  |  | 1,639 |  |  | 1,327 |  |  | 23.5 |  | 23.5 |  | 0.0
UPTRAVI |  |  |  |  |  |  |  |  |
US |  |  | 955 |  |  | 714 |  |  | 33.8 |  | 33.8 |  | —
Intl |  |  | 138 |  |  | 105 |  |  | 30.9 |  | 30.5 |  | 0.4
WW |  |  | 1,093 |  |  | 819 |  |  | 33.5 |  | 33.4 |  | 0.1
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |
US |  |  | 169 |  |  | 205 |  |  | (17.6) |  | (17.6) |  | —
Intl |  |  | 247 |  |  | 272 |  |  | (9.2) |  | (9.4) |  | 0.2
WW |  |  | 416 |  |  | 476 |  |  | (12.8) |  | (12.9) |  | 0.1
CARDIOVASCULAR / METABOLISM / OTHER |  |  |  |  |  |
US |  |  | 3,509 |  |  | 3,734 |  |  | (6.0) |  | (6.0) |  | —
Intl |  |  | 1,369 |  |  | 1,458 |  |  | (6.1) |  | (4.8) |  | (1.3)
WW |  |  | 4,878 |  |  | 5,192 |  |  | (6.0) |  | (5.7) |  | (0.3)
XARELTO |  |  |  |  |  |  |  |  |
US |  |  | 2,345 |  |  | 2,313 |  |  | 1.4 |  | 1.4 |  | —
Intl |  |  | — |  |  | — |  |  | — |  | — |  | —
WW |  |  | 2,345 |  |  | 2,313 |  |  | 1.4 |  | 1.4 |  | —
INVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |
US |  |  | 564 |  |  | 536 |  |  | 5.2 |  | 5.2 |  | —
Intl |  |  | 231 |  |  | 199 |  |  | 16.3 |  | 17.6 |  | (1.3)
WW |  |  | 795 |  |  | 735 |  |  | 8.2 |  | 8.6 |  | (0.4)
PROCRIT / EPREX |  |  |  |  |  |  |  |  |
US |  |  | 277 |  |  | 505 |  |  | (45.1) |  | (45.1) |  | —
Intl |  |  | 274 |  |  | 285 |  |  | (3.8) |  | (3.6) |  | (0.2)
WW |  |  | 552 |  |  | 790 |  |  | (30.2) |  | (30.1) |  | (0.1)
OTHER |  |  |  |  |  |  |  |  |
US |  |  | 323 |  |  | 380 |  |  | (15.1) |  | (15.1) |  | —
Intl |  |  | 864 |  |  | 974 |  |  | (11.3) |  | (9.7) |  | (1.6)
WW |  |  | 1,186 |  |  | 1,353 |  |  | (12.4) |  | (11.2) |  | (1.2)
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |
US |  |  | 25,735 |  |  | 23,874 |  |  | 7.8 |  | 7.8 |  | —
Intl |  |  | 19,837 |  |  | 18,324 |  |  | 8.3 |  | 8.8 |  | (0.5) |
WW |  | $ | 45,572 |  |  | 42,198 |  |  | 8.0 | % | 8.2 | % | (0.2) | %
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | TWELVE MONTHS
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
MEDICAL DEVICES SEGMENT (2) (5) |  |  |  |  |  |
INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |
US |  | $ | 1,452 |  |  | 1,443 |  |  | 0.6 | % | 0.6 | % | — | %
Intl |  |  | 1,594 |  |  | 1,554 |  |  | 2.6 |  | 2.0 |  | 0.6 |
WW |  |  | 3,046 |  |  | 2,997 |  |  | 1.6 |  | 1.3 |  | 0.3 |
ORTHOPAEDICS |  |  |  |  |  |  |  |  |
US |  |  | 4,779 |  |  | 5,319 |  |  | (10.2) |  | (10.2) |  | —
Intl |  |  | 2,984 |  |  | 3,520 |  |  | (15.2) |  | (15.4) |  | 0.2 |
WW |  |  | 7,763 |  |  | 8,839 |  |  | (12.2) |  | (12.3) |  | 0.1 |
HIPS |  |  |  |  |  |  |  |  |
US |  |  | 793 |  |  | 863 |  |  | (8.2) |  | (8.2) |  | —
Intl |  |  | 487 |  |  | 575 |  |  | (15.3) |  | (15.1) |  | (0.2) |
WW |  |  | 1,280 |  |  | 1,438 |  |  | (11.0) |  | (11.0) |  | 0.0 |
KNEES |  |  |  |
US |  |  | 743 |  |  | 889 |  |  | (16.4) |  | (16.4) |  | —
Intl |  |  | 427 |  |  | 591 |  |  | (27.8) |  | (28.0) |  | 0.2 |
WW |  |  | 1,170 |  |  | 1,480 |  |  | (21.0) |  | (21.1) |  | 0.1 |
TRAUMA |  |  |  |  |  |  |  |  |
US |  |  | 1,648 |  |  | 1,652 |  |  | (0.2) |  | (0.2) |  | —
Intl |  |  | 966 |  |  | 1,068 |  |  | (9.6) |  | (9.7) |  | 0.1 |
WW |  |  | 2,614 |  |  | 2,720 |  |  | (3.9) |  | (3.9) |  | 0.0 |
SPINE, SPORTS & OTHER (7) |  |
US |  |  | 1,595 |  |  | 1,915 |  |  | (16.7) |  | (16.7) |  | —
Intl |  |  | 1,104 |  |  | 1,286 |  |  | (14.1) |  | (14.6) |  | 0.5 |
WW |  |  | 2,699 |  |  | 3,201 |  |  | (15.7) |  | (15.9) |  | 0.2 |
See footnotes at end of schedule |  |  |  |  |  |  |  |  |

Johnson & Johnson
Segment Sales
(Dollars in Millions)
|  |  | TWELVE MONTHS
|  |  |  |  |  |  | % Change
|  |  | 2020 |  | 2019 |  | Reported | Operational (1) | Currency
MEDICAL DEVICES SEGMENT (2) (5) (Continued) |  |  |  |  |  |
SURGERY |  |  |  |  |  |
US |  | $ | 3,249 |  |  | 3,828 |  |  | (15.1) | % | (15.1) | % | — | %
Intl |  |  | 4,983 |  |  | 5,673 |  |  | (12.2) |  | (11.2) |  | (1.0) |
WW |  |  | 8,232 |  |  | 9,501 |  |  | (13.4) |  | (12.8) |  | (0.6) |
ADVANCED |  |  |  |  |  |  |  |  |
US |  |  | 1,535 |  |  | 1,637 |  |  | (6.2) |  | (6.2) |  | —
Intl |  |  | 2,304 |  |  | 2,458 |  |  | (6.2) |  | (5.6) |  | (0.6) |
WW |  |  | 3,839 |  |  | 4,095 |  |  | (6.2) |  | (5.8) |  | (0.4) |
GENERAL |  |  |  |  |  |  |  |  |
US |  |  | 1,714 |  |  | 2,192 |  |  | (21.8) |  | (21.8) |  | —
Intl |  |  | 2,679 |  |  | 3,215 |  |  | (16.7) |  | (15.5) |  | (1.2) |
WW |  |  | 4,392 |  |  | 5,406 |  |  | (18.8) |  | (18.0) |  | (0.8) |
VISION |  |  |  |
US |  |  | 1,557 |  |  | 1,794 |  |  | (13.2) |  | (13.2) |  | —
Intl |  |  | 2,362 |  |  | 2,830 |  |  | (16.5) |  | (16.2) |  | (0.3) |
WW |  |  | 3,919 |  |  | 4,624 |  |  | (15.2) |  | (15.1) |  | (0.1) |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |
US |  |  | 1,213 |  |  | 1,304 |  |  | (7.0) |  | (7.0) |  | —
Intl |  |  | 1,781 |  |  | 2,088 |  |  | (14.7) |  | (14.4) |  | (0.3) |
WW |  |  | 2,994 |  |  | 3,392 |  |  | (11.7) |  | (11.5) |  | (0.2) |
SURGICAL |  |  |  |  |  |  |  |  |
US |  |  | 344 |  |  | 490 |  |  | (29.7) |  | (29.7) |  | —
Intl |  |  | 581 |  |  | 742 |  |  | (21.7) |  | (21.5) |  | (0.2) |
WW |  |  | 925 |  |  | 1,232 |  |  | (24.9) |  | (24.7) |  | (0.2) |
TOTAL MEDICAL DEVICES |  |
US |  |  | 11,036 |  |  | 12,384 |  |  | (10.9) |  | (10.9) |  | —
Intl |  |  | 11,923 |  |  | 13,579 |  |  | (12.2) |  | (11.8) |  | (0.4) |
WW |  | $ | 22,959 |  |  | 25,963 |  |  | (11.6) | % | (11.4) | % | (0.2) | %
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency |  |
(2) Unaudited |  |  |  |  |  |  |  |  |
(3) Previously referred to as Consumer |  |  |  |  |  |  |  |  |
(4) Previously referred to as Beauty |
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
(6) Reported as U.S. sales
(7) Previously referred to as Spine & Other